Medigen Vaccine Biologics Corp , the first private manufacturer, is offering its patent and know-how for a COVID-19 vaccine that has seen more than three million doses administered across seven countries. It is the first time that a vaccine manufacturer is using the WHO C-TAP model - a win-win opportunity for the manufacturer, recipients of the technology and, most importantly, patients in need around the world. The agreement will enable licensing of IP facilitating technology transfer and staff training.Spanish National Research Council (CSIC) is sharing a second license for a COVID-19 vaccine prototype. The agreement includes plant visits and training, direct assistance and ongoing consultation with recipient manufacturers, including on quality and regulatory matters.The University of Chile is sharing its technology for a COVID-19 assay for quantification of neutralizing antibodies.
C-TAP was launched in
C-TAP was acknowledged as an important tool in the 2021 " Local Production Resolution" to facilitate sustainable access to quality-assured, safe, effective and affordable medicines and other health technologies. Furthermore, it has played an important role in raising awareness of the role of technology and knowledge sharing and access-oriented voluntary licensing.
"COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it," said Dr
During the height of the COVID-19 pandemic only two public health
Addition of the three new licenses now provides an important boost to the overall effort. The new licenses are global, transparent and non-exclusive to all manufacturers and are accessible on the C-TAP website. Importantly, the first license, on a serological test, resulted in a sub license to Biotech Africa from CSIC to develop their diagnostic technology.
C-TAP has also established a
Quotes from the organizations signing new C-TAP licenses
Charles Chen , CEO ofMedigen Vaccine Biologics Corp. stated, "We believe that the most effective response to a pandemic must be rooted in solidarity, cooperation, and collective global effort. By joining the C-TAP initiative, we are providing equitable access to our vaccine technology. It underscores our commitment to ensure that vaccines reach all corners of the globe, leaving no one behind. This is not just about COVID-19, it is about setting a precedent for future global health challenges. By demonstrating our commitment to open science and cooperative strategies. We hope to inspire other organizations to follow suit. To all those that trusted, participated, collaborated, and supported us, thank you! For without you, we could not make this C-TAP initiative possible."University of Chile Rector , Professor Dr. Rosa Devés Alessandri, said, "For theUniversity of Chile , the achievement of our scientists, is a source of pride and an encouragement for the advancement of biomedical research in our country. It shows how excellent research carried out internationally has the capacity to offer solutions with a high social impact in the field of health. We thank all the organisations that have made it possible for theUniversity of Chile to contribute to global health".Eloisa del Pino , President of CSIC said 'This licensing agreement with C-TAP opens the possibility of finding partners in third countries to advance clinical trials with this vaccine as a future alternative to licensed COVID vaccine options worldwide, especially in resource-poor countries."
About C-TAP
C-TAP was launched in 2020 by the WHO Director-General and the President of
WHO technical teams support by providing assessment of technologies to technology givers and receivers. This includes the recently launched WHO-Unitaid briefing document to support how to navigate interfaces between public health and intellectual property.
AboutMPP
The
Copyright World Health Organization. Distributed by AllAfrica Global Media (allAfrica.com)., source